On Monday, Jefferies began coverage on shares of NASDAQ:PHAR, Pharming Group, with a positive outlook, assigning the stock a Buy rating and setting a price target of $14.00. The pharmaceutical company, currently valued at $565 million, has shown strong revenue growth of 31% over the last twelve months.
The company has two key drugs in its portfolio: Ruconest, for treating hereditary angioedema (HAE), has been approved since 2010, and Joenja, aimed at activated PI3K-delta syndrome (APDS), received U.S. approval in April 2023.
Pharming's strategy revolves around the commercialization of treatments for ultra-rare diseases. These conditions offer potentially high-value markets as patients typically receive care from specialized centers and are often connected with disease-specific organizations. This dynamic allows for a streamlined sales process with a smaller salesforce and reduced overhead costs, which in turn can lead to higher profitability.
According to InvestingPro data, this approach has resulted in impressive gross profit margins of 89% and strong liquidity, with current assets exceeding short-term obligations by more than 3.5 times.
The company is actively seeking to expand its portfolio by acquiring additional late-stage assets in the rare disease category. This strategy could not only boost Pharming's revenue but also increase profit margins, especially if the new assets can be integrated within the existing commercial framework.
Currently, Pharming's sales are predominantly in the U.S. market. However, with the anticipated approvals of Joenja, the company is expected to tap into new commercial opportunities in other significant markets, including Europe and Japan, starting from 2026. While this expansion presents a promising avenue for growth, it also introduces potential risks associated with executing the strategy in these new territories.
InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $30 to $37, indicating significant potential upside. For deeper insights into Pharming's growth prospects and financial health, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Pharming Group NV reported a 12% quarter-over-quarter increase in Q3 revenues, totaling $74.8 million, slightly below the $78 million expected by Oppenheimer and consensus estimates.
Despite the lower-than-expected revenue, the company confirmed its full-year 2024 revenue guidance to be between $280 million and $295 million. Following the earnings report, Oppenheimer revised its revenue estimate for Pharming Group down from $297 million to $287 million for the year.
The company's key product, Ruconest, is facing uncertainty due to the expected FDA approval of a competitor in June 2025. Additionally, the upcoming retirement of long-time CEO Sijmen de Vries introduces further uncertainty. Despite these challenges, Pharming Group's product sales showed robust growth, particularly Joenja, which grew by a substantial 73%.
In light of these recent developments, Oppenheimer has maintained an Outperform rating for Pharming Group, albeit with a revised price target. The company continues to focus on expanding its pipeline and in-licensing opportunities, with a particular emphasis on increasing its market reach in Japan and Australia.
While the company reported a net loss in Q3, year-to-date revenues reached $204.5 million, demonstrating resilience and growth potential amid significant leadership changes and a challenging global healthcare landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.